


Claim Amendments

1. (Currently Amended) A compound of the formula



wherein

~~Y is $\text{CH}=\text{CH}$, $\text{CH}=\text{N}$, sulfur or oxygen; and~~

M is hydrogen, halo, lower alkyl, or perfluoro lower alkyl; and

R_x and R_y are hydrogen, halo or methyl; and

R¹ and R² are independently hydrogen, halo, amino, hydroxyamino, nitro, cyano, sulfonamido, lower alkyl, -OR⁵, -COOR⁵, perfluoro- lower alkyl, lower alkyl thio, perfluoro-lower alkyl thio, lower alkyl sulfonyl, perfluoro lower alkyl sulfonyl, lower alkyl sulfinyl,

R⁵ is hydrogen, lower alkyl or perfluoro-lower alkyl; or furthermore

R¹, R² can be $-(\text{CH}_2)_n\text{-NR}^6\text{R}^7$, with n=1, 2, 3 or 4 and

R⁶ and R⁷ are independently hydrogen or lower alkyl; or together with the nitrogen atom to which they are attached form a five or six-membered heteroaromatic ring containing from 1 to 3 heteroatoms selected from sulfur, oxygen or nitrogen; or a saturated 5- or 6-membered cycloheteroalkyl ring, which contains from 1 to 2 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen; or

~~R¹, R² can be alkynylalkynyl,~~

substituted with hydrogen, lower alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl, an unsubstituted or hydroxy substituted cycloalkyl ring containing 5 or 6 carbon atoms, a five- or

six-membered saturated heterocyclic ring which contains from 1 to 3 hetero atoms selected from the group consisting of sulfur, oxygen or nitrogen, or an unsubstituted five- or six-membered heteroaromatic ring, connected by a ring carbon atom, which contains from 1 to 3 heteroatoms in the ring selected from the group consisting of sulfur, nitrogen and oxygen, or $-(CH_2)_n-NR^8R^9$, with $n=1, 2$, and

R^8 and R^9 are independently hydrogen or lower alkyl; or together with the nitrogen atom to which they are attached form a five or six-membered heteroaromatic ring containing from 1 to 3 heteroatoms selected from sulfur, oxygen or nitrogen; or a saturated 5- or 6-membered cycloheteroalkyl ring, which contains from 1 to 2 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen; or

R^1, R^2 can be $R^{10}-[(CH_2)_y-W]_z-$, with

W is oxygen, sulfur, $-SO-$, $-SO_2-$, and

R^{10} is a heteroaromatic ring, connected by a ring carbon atom, which contains from 5 to 6 ring members with from 1 to 2 heteroatoms selected from the group consisting of oxygen, sulfur or nitrogen, or

aryl containing 6 or 10 ring carbon atoms, or

aryl containing from 6 ring carbon atoms fused with a heteroaromatic ring containing 5 or 6 ring members with 1 or 2 heteroatoms in the ring being selected from the group consisting of nitrogen, oxygen or sulfur, or

a saturated 5- or 6-membered cycloheteroalkyl ring, which contains from 1 to 2 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen, or

a cycloalkyl ring having 5 or 6 carbon atoms, or

$-NR^{11}R^{12}$, with R^{11} and R^{12} are independently hydrogen or lower alkyl;

y is independently 0, 1, 2, 3 or 4; z is independently 0,1; or

R^1, R^2 can be $R^{13}-(CH_2)_t-U-$, with

U is $-NHCO-$, $-CONH-$, $-NHSO_2-$, $-SO_2NH-$ and

R^{13} in the same meaning of R^{10} and

perfluoro-lower alkyl, lower alkyl, lower alkoxy carbonyl or

$-NR^{14}R^{15}$, R^{14} and R^{15} are independently hydrogen or lower alkyl; or together with the nitrogen atom to which they are attached form a five or six-membered heteroaromatic ring containing from 1 to 3 heteroatoms selected from sulfur, oxygen or nitrogen; or a saturated 5- or 6-

membered heterocycloalkyl ring, which contains from 1 to 2 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen;

t is an integer being 0, 1, 2, 3 or 4;

R^3 is lower alkyl or halo lower alkyl having from 2 to 6 carbon atoms or arylalkyl or $-(CH_2)_s-V$ where V is a 3 to 8-membered ring which is cycloalkyl, cycloalkenyl, or heterocycloalkyl having one heteroatom selected from oxygen and sulfur;

s is independently 0, 1 or 2;

R^4 is $-C(O)NHR^{16}$, or is R^{17} ;

R^{16} is hydrogen, lower alkyl, lower alkenyl, hydroxy lower alkyl,

$-(CH_2)_n-COOR^{18}$, $-CO-(CH_2)_n-COOR^{19}$;


R^{17} is an unsubstituted, mono- or di-substituted five- or six-membered heteroaromatic ring connected by a ring carbon atom to the amide group shown, which five- or six-membered heteroaromatic ring contains from 1 to 4 heteroatoms selected from sulfur, oxygen or nitrogen, with one heteroatom being nitrogen which is adjacent to the connecting ring carbon atom; said mono- or di-substituted heteroaromatic ring being mono- or di-substituted at a position on a ring carbon atom other than adjacent to said connecting carbon atom with a substituent selected from the group consisting of lower alkyl, halo, nitro, cyano, $-(CH_2)_n-OR^{20}$, $-(CH_2)_n-COOR^{21}$, $-(CH_2)_n-CONHR^{22}$, $-(CH_2)_n-NHR^{23}$,

n is 0, 1, 2, 3 or 4;

R^{18} , R^{19} , R^{20} , R^{21} , R^{22} and R^{23} are independently hydrogen or lower alkyl,

and its pharmaceutically acceptable salts thereof.

2. (Currently Amended) A compound according to claim 1 having the formula



wherein

M is hydrogen, halo, lower alkyl or perfluoro lower alkyl; and

R_x and R_y are hydrogen, halo or methyl; and

R¹ and R² are independently hydrogen, halo, amino, hydroxyamino, nitro, cyano, sulfonamido, lower alkyl, -OR⁵, -COOR⁵, perfluoro- lower alkyl, lower alkyl thio, perfluoro-lower alkyl thio, lower alkyl sulfonyl, perfluoro lower alkyl sulfonyl, lower alkyl sulfinyl,

R⁵ is hydrogen, lower alkyl or perfluoro-lower alkyl; or furthermore

R¹, R² can be -(CH₂)_n-NR⁶R⁷, with n=1, 2, 3 or 4 and

R⁶ and R⁷ are independently hydrogen or lower alkyl; or together with the nitrogen atom to which they are attached form a five or six-membered heteroaromatic ring containing from 1 to 3 heteroatoms selected from sulfur, oxygen or nitrogen; or a saturated 5- or 6-membered cycloheteroalkyl ring, which contains from 1 to 2 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen; or

R₁, R₂ can be ~~alkenyl~~alkynyl,

substituted with hydrogen, lower alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl, an unsubstituted or hydroxy substituted cycloalkyl ring containing 5 or 6 carbon atoms, a five- or six-membered saturated heterocyclic ring which contains from 1 to 3 hetero atoms selected from the group consisting of sulfur, oxygen or nitrogen, or an unsubstituted five- or six-membered heteroaromatic ring, connected by a ring carbon atom, which contains from 1 to 3 heteroatoms in the ring selected from the group consisting of sulfur, nitrogen and oxygen, or -(CH₂)_n-NR₈R₉, with n=1, 2, and

R₈ and R₉ are independently hydrogen or lower alkyl; or together with the nitrogen atom to which they are attached form a five or six-membered heteroaromatic ring containing from 1 to 3 heteroatoms selected from sulfur, oxygen or nitrogen; or a saturated 5- or 6-membered cycloheteroalkyl ring, which contains from 1 to 2 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen; or

R₁, R₂ can be R₁₀-[(CH₂)_y-W]_z-, with

W is oxygen, sulfur, -SO-, -SO₂-, and

R₁₀ is a heteroaromatic ring, connected by a ring carbon atom, which contains from 5 to 6 ring members with from 1 to 2 heteroatoms selected from the group consisting of oxygen, sulfur or nitrogen, or

aryl containing 6 or 10 ring carbon atoms, or

aryl containing from 6 ring carbon atoms fused with a heteroaromatic ring containing 5 or 6 ring members with 1 or 2 heteroatoms in the ring being selected from the group consisting of nitrogen, oxygen or sulfur, or

a saturated 5- or 6-membered cycloheteroalkyl ring, which contains from 1 to 2 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen, or

a cycloalkyl ring having 5 or 6 carbon atoms, or

$-NR^{11}R^{12}$, with R^{11} and R^{12} are independently hydrogen or lower alkyl;

y is independently 0, 1, 2, 3 or 4; z is independently 0, or 1; or

R^1, R^2 can be $R^{13}-(CH_2)_t-U-$, with

U is $-NHCO-$, $-CONH-$, $-NHSO_2-$, $-SO_2NH-$ and

R^{13} in the same meaning of R^{10} and

perfluoro-lower alkyl, lower alkyl, lower alkoxy carbonyl or

$-NR^{14}R^{15}$, R^{14} and R^{15} are independently hydrogen or lower alkyl; or together with the nitrogen atom to which they are attached form a five or six-membered heteroaromatic ring containing from 1 to 3 heteroatoms selected from sulfur, oxygen or nitrogen; or a saturated 5- or 6-membered heterocycloalkyl ring, which contains from 1 to 2 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen;

t is an integer being 0, 1, 2, 3 or 4;

R^3 is lower alkyl or halo lower alkyl having from 2 to 6 carbon atoms or arylalkyl or $-(CH_2)_s-V$ where V is a 3 to 8-membered ring which is cycloalkyl, cycloalkenyl, or heterocycloalkyl having one heteroatom selected from oxygen and sulfur;

s is independently 0, 1 or 2;

R^4 is $-C(O)NHR^{16}$, or is R^{17} ;

R^{16} is hydrogen, lower alkyl, lower alkenyl, hydroxy lower alkyl,

$-(CH_2)_n-COOR^{18}$, $-CO-(CH_2)_n-COOR^{19}$;

R^{17} is an unsubstituted, mono- or di-substituted five- or six-membered heteroaromatic ring connected by a ring carbon atom to the amide group shown, which five- or six-membered heteroaromatic ring contains from 1 to 4 heteroatoms selected from sulfur, oxygen or nitrogen, with one heteroatom being nitrogen which is adjacent to the connecting ring carbon atom; said mono- or di-substituted heteroaromatic ring being mono- or di-substituted at a position on a ring

carbon atom other than adjacent to said connecting carbon atom with a substituent selected from the group consisting of lower alkyl, halo, nitro, cyano, $-(CH_2)_n-OR^{20}$, $-(CH_2)_n-COOR^{21}$, $-(CH_2)_n-CONHR^{22}$, $-(CH_2)_n-NHR^{23}$,
n is 0, 1, 2, 3 or 4;
 R^{18} , R^{19} , R^{20} , R^{21} , R^{22} and R^{23} are independently hydrogen or lower alkyl,
and its pharmaceutically acceptable salts thereof.

3. (Canceled)

4. (Previously Presented) A compound according to claim 1, wherein
 R^4 is an unsubstituted, mono- or di-substituted five- or six-membered heteroaromatic ring connected by a ring carbon atom to the amide group shown, which five- or six-membered heteroaromatic ring contains from 1 to 4 heteroatoms selected from sulfur, oxygen or nitrogen, with one heteroatom being nitrogen which is adjacent to the connecting ring carbon atom; said mono- or di-substituted heteroaromatic ring being mono- or di-substituted at a position on a ring carbon atom other than adjacent to said connecting carbon atom with a substituent selected from the group consisting of lower alkyl, halo, nitro, cyano, $-(CH_2)_n-OR^{20}$, $-(CH_2)_n-COOR^{21}$, $-(CH_2)_n-CONHR^{22}$, $-(CH_2)_n-NHR^{23}$,
n is 0, 1, 2, 3 or 4;
 R^{20} , R^{21} , R^{22} and R^{23} are independently hydrogen or lower alkyl,
and its pharmaceutically acceptable salts thereof.

5. (Previously Presented) A compound according to claim 4, wherein R^4 is an unsubstituted mono- or di-substituted five- or six-membered heteroaromatic ring selected from the group consisting of thiazolyl, imidazolyl, oxazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, or triazinyl.

6. (Previously Presented) A compound according to claim 5, wherein R^4 is thiazolyl or pyridinyl, unsubstituted, mono- or di-substituted independently by halogen, lower alkyl or $(CH_2)_n-C(O)OR^{21}$, wherein n is 0, 1 or 2 and R^{21} is lower alkyl.

7. (Previously Presented) A compound according to claim 1, wherein R^4 is $-C(O)NHR^{16}$, where R^{16} is hydrogen, lower alkyl, lower alkenyl, hydroxy lower alkyl, $-(CH_2)_n-COOR^{18}$, $-CO-(CH_2)_n-COOR^{19}$; n is 0, 1, 2, 3 or 4; R^{18} and R^{19} are independently hydrogen or lower alkyl, and its pharmaceutically acceptable salts thereof.
8. (Previously Presented) A compound according to claim 7, wherein R^4 is $-C(O)NHR^{16}$, and R^{16} is lower alkyl or lower alkenyl.
9. (Previously Presented) A compound according to claim 6, wherein R^1 is hydrogen, halo, nitro or cyano.
10. (Previously Presented) A compound according to claim 9, wherein R^1 is hydrogen or halo.
11. (Currently Amended) A compound according to claim 10, wherein R^2 is hydrogen, halo, nitro, cyano, sulfonamido, lower alkyl, $-OR^5$, $-COOR^5$, perfluoro- lower alkyl, lower alkyl sulfonyl; or R^2 can be $R^{10}-[(CH_2)_y-W]_z-$, where W is oxygen, sulfur, $-SO-$, or $-SO_2-$, and R^{10} is a heteroaromatic ring, connected by a ring carbon atom, which contains from 5 to 6 ring members with from 1 to 2 heteroatoms selected from the group consisting of oxygen, sulfur or nitrogen, or aryl containing 6 or 10 ring carbon atoms, or aryl containing 6 ring carbon atoms fused with a heteroaromatic ring containing 5 or 6 ring members with 1 or 2 heteroatoms in the ring being selected from the group consisting of nitrogen, oxygen or sulfur, or a saturated 5- or 6-membered cycloheteroalkyl ring, which contains from 1 to 2 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen, or a cycloalkyl ring having 5 or 6 carbon atoms, or

$\text{-NR}^{11}\text{R}^{12}$, with R^{11} and R^{12} being independently hydrogen or lower alkyl;
y is independently 0,1,2,3 or 4; z is independently 0, or 1; or
 R^2 can be $\text{R}^{13}\text{-(CH}_2\text{)}_t\text{-U-}$, with
U is -NHCO- , -CONH- , $\text{-NHSO}_2\text{-}$, $\text{-SO}_2\text{NH-}$ and
 R^{13} in the same meaning of R^{10} and
perfluoro-lower alkyl, lower alkyl, lower alkoxy carbonyl or
 $\text{-NR}^{14}\text{R}^{15}$, R^{14} and R^{15} are independently hydrogen or lower alkyl; or together with the nitrogen
atom to which they are attached form a five or six-membered heteroaromatic ring containing
from 1 to 3 heteroatoms selected from sulfur, oxygen or nitrogen;
t is an integer from 0 to 4.

12. (Previously Presented) A compound according to claim 11, wherein R^2 is halo, lower alkyl
sulfonyl or $\text{R}^{10}\text{-[(CH}_2\text{)}_y\text{-W]}_z\text{-}$.

13. (Previously Presented) A compound according to claim 12, wherein R^2 is sulfonylmethyl or
 $\text{R}^{10}\text{-[(CH}_2\text{)}_y\text{-W]}_z\text{-}$ where W is SO_2 .

14. (Previously Presented) A compound according to claim 13, wherein the aryl substituent and
the group R^3 have a syn-relationship.

15. (Previously Presented) A compound according to claim 14, wherein V is cyclopentyl,
cyclohexyl or cycloheptyl.

16. (Previously Presented) A compound according to claim 14, wherein V is cyclopentyl or
cyclohexyl.

17. (Previously Presented) A compound according to claim 14, wherein R^3 is isopropyl or n-
propyl.

18. (Previously Presented) A compound according to claim 14, wherein R^3 is isobutyl.

19. (Canceled)

20. (Previously Presented) A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

21. (Canceled)

22. (Currently Amended) A method for the prophylactic or therapeutic treatment of type II diabetes, which comprises ~~administering~~administering a compound of claim 1, or a pharmaceutically acceptable salt thereof, to a human being or animal in need thereof.

23. (Canceled)

24. (Currently Amended) A compound of claim 1 selected from the group consisting of:

- (±)-(E)-2-Cyclohexyl-1-(4-methanesulfonyl-phenyl)-cyclopropanecarboxylic acid (5-chloro-thiazol-2-yl)-amide;
- (±)-(E)-2-Cyclohexylmethyl-1-(4-methanesulfonyl-phenyl)-cyclopropanecarboxylic acid thiazol-2-ylamide;
- (±)-(E)- 2-Isobutyl-1-(4-methanesulfonyl-phenyl)-cyclopropanecarboxylic acid thiazol-2-ylamide;
- (±)-(E)-1-(4-Methanesulfonyl-phenyl)-2-(3-methyl-butyl)-cyclopropanecarboxylic acid thiazol-2-ylamide;
- (±)-(E)-2-(2,2-Dimethyl-propyl)-1-(4-methanesulfonyl-phenyl)-cyclopropanecarboxylic acid thiazol-2-ylamide;
- (±)-(E)-2-Cyclopentyl-1-[4-(3-diethylamino-propane-1-sulfonyl)-phenyl]-cyclopropanecarboxylic acid thiazol-2-ylamide;
- (±)-(E)-2-Cyclohexyl-1-[4-(3-diethylamino-propane-1-sulfonyl)-phenyl]-cyclopropanecarboxylic acid thiazol-2-ylamide;
- (±)-(E)-1-(3-Chloro-4-sulfamoyl-phenyl)-2-cyclohexyl-cyclopropanecarboxylic acid thiazol-2-ylamide;

(±)-(E)-2-Cyclohexyl-1-[4-(propane-2-sulfonyl)-phenyl]-cyclopropanecarboxylic acid thiazol-2-ylamide;

(±)-(E)-2-Cyclohexyl-1-[4-(propane-2-sulfonyl)-phenyl]-cyclopropanecarboxylic acid [1,3,4]thiadiazol-2-ylamide;

(±)-(E)-2-Cyclopentyl-1-(4-methanesulfonyl-phenyl)-cyclopropanecarboxylic acid (5-methyl-[1,3,4]thiadiazol-2-yl)-amide;

(±)-(E)-2-Cyclopentyl-1-(4-methanesulfonyl-phenyl)-cyclopropanecarboxylic acid isoxazol-3-ylamide;

(±)-(E)-2-Cyclopentyl-1-(4-methanesulfonyl-phenyl)-cyclopropanecarboxylic acid (5-methyl-isoxazol-3-yl)-amide;

(±)-(E)-(2-{[2-Cyclopentyl-1-(4-methanesulfonyl-phenyl)-cyclopropanecarbonyl]-amino}-thiazol-4-yl)-acetic acid ethyl ester;

(±)-(E)-(2-{[2-Cyclopentyl-1-(4-methanesulfonyl-phenyl)-cyclopropanecarbonyl]-amino}-thiazole-4-carboxylic acid ethyl ester;

~~(±)-(Z)-2-Cyclopentylmethyl-1-(5-methanesulfonyl-thiophen-2-yl)-cyclopropanecarboxylic acid thiazol-2-ylamide;~~

~~(±)-(Z)-2-Cyclohexyl-1-(5-methanesulfonyl-thiophen-2-yl)-cyclopropanecarboxylic acid thiazol-2-ylamide;~~

~~(±)-(Z)-2-Cyclopentyl-1-(5-methanesulfonyl-thiophen-2-yl)-cyclopropanecarboxylic acid thiazol-2-ylamide;~~

~~(Z)-2-Cyclopentyl-1-(5-methanesulfonyl-thiophen-2-yl)-cyclopropanecarboxylic acid thiazol-2-ylamide;~~

~~(±)-(Z)-2-Cyclopentyl-1-(4-methanesulfonyl-thiophen-2-yl)-cyclopropanecarboxylic acid thiazol-2-ylamide;~~

~~(±)-(Z)-5-[2-Cyclohexyl-1-(thiazol-2-ylcarbamoyl)-cyclopropyl]-thiophene-2-carboxylic acid (2-dimethylamino-ethyl)-amide;~~

~~(±)-(Z)-5-[2-Cyclohexyl-1-(thiazol-2-ylcarbamoyl)-cyclopropyl]-thiophene-2-carboxylic acid ethyl ester;~~

~~(±)-(Z)-2-Cyclopentyl-1-(5-sulfamoyl-thiophen-2-yl)-cyclopropanecarboxylic acid thiazol-2-ylamide;~~

~~(±)-(E)-2-Cyclopentyl-1-(5-methanesulfonyl-thiophen-3-yl)-cyclopropanecarboxylic acid thiazol-2-ylamide;~~

~~(Z)-1-(5-Bromo-thiophen-2-yl)-2-cyclohexyl-cyclopropanecarboxylic acid thiazol-2-ylamide, enantiomer 1;~~

(E)-2-Cyclopentyl-1-[4-(2-pyridin-2-yl-ethylsulfamoyl)-phenyl]-cyclopropanecarboxylic acid thiazol-2-ylamide;

(E)-2-Cyclopentyl-1-[4-(2-pyridin-2-yl-ethylsulfamoyl)-phenyl]-cyclopropanecarboxylic acid thiazol-2-ylamide;

(±)-(E)-2-Cyclopentyl-1-{4-[(pyridin-3-ylmethyl)-sulfamoyl]-phenyl}-cyclopropanecarboxylic acid thiazol-2-ylamide;

(±)-(E)-2-Cyclopentyl-1-(4-methanesulfonyl-phenyl)-cyclopropanecarboxylic acid thiazol-2-ylamide;

(±)-(E)-2,2-Dichloro-3-cyclopentyl-1-(4-methanesulfonyl-phenyl)-cyclopropanecarboxylic acid thiazol-2-ylamide;

(±)-(E)-3-Cyclopentyl-2,2-difluoro-1-(4-methanesulfonyl-phenyl)-cyclopropanecarboxylic acid thiazol-2-ylamide;

(±)-(E)-2-Cyclohexyl-1-(4-fluoro-phenyl)-cyclopropanecarboxylic acid thiazol-2-ylamide ;

(±)-(E)-2-Cyclohexyl-1-(3-methanesulfonyl-phenyl)-cyclopropanecarboxylic acid thiazol-2-ylamide;

(±)-(E)-2-Cyclohexyl-1-(3-fluoro-4-methanesulfonyl-phenyl)-cyclopropanecarboxylic acid thiazol-2-ylamide;

(±)-(E)-2-Cyclopentyl-1-[4-(3-imidazol-1-yl-propylsulfamoyl)-phenyl]-cyclopropanecarboxylic acid thiazol-2-ylamide;

(E)-2-Cyclohexyl-1-(4-methanesulfonyl-phenyl)-cyclopropanecarboxylic acid (5-fluoro-thiazol-2-yl)-amide;

(±)-(E)-2-Cyclopentyl-1-[4-(pyridin-3-ylmethanesulfonyl)-phenyl]-cyclopropanecarboxylic acid (5-chloro-thiazol-2-yl)-amide;

(±)-(E)-2-Cyclopentyl-1-[4-(pyridin-3-ylmethanesulfonyl)-phenyl]-cyclopropanecarboxylic acid thiazol-2-ylamide

(±)-(E)-2-Cyclohexyl-1-(4-methylsulfonyl-phenyl)-cyclopropanecarboxylic acid thiazol-2-ylamide;

(±)-(E)-2-Cyclohexyl-1-(4-methanesulfonyl-3-trifluoromethoxy-phenyl)-cyclopropanecarboxylic acid thiazol-2-ylamide;

(±)-(E)-2-Cyclohexyl-1-(4-methanesulfonyl-3-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid thiazol-2-ylamide;

(±)-(E)-2-Cyclohexyl-1-(4-nitro-phenyl)-cyclopropanecarboxylic acid thiazol-2-ylamide;

(±)-(E)- 3-[2-Cyclohexyl-1-(thiazol-2-ylcarbamoyl)-cyclopropyl]-benzoic acid; (±)-(E)-[2-Cyclohexyl-1-(4-methoxy-phenyl)-cyclopropanecarboxylic acid thiazol-2-ylamide];

(±)-(E)-4-[2-Cyclohexyl-1-(thiazol-2-ylcarbamoyl)-cyclopropyl]-*N*-pyridin-3-ylmethyl-benzamide;

(±)-(E)-4-[2-Cyclohexyl-1-(thiazol-2-ylcarbamoyl)-cyclopropyl]-*N*-methyl-benzamide;

(±)-(E)-1-(4-Acetylamino-phenyl)-2-cyclohexyl-cyclopropanecarboxylic acid thiazol-2-ylamide;

(±)-(E)-2-Cyclohexyl-1-(4-methanesulfonylamino-phenyl)-cyclopropanecarboxylic acid thiazol-2-ylamide;

~~(±)-(E)-2-Cyclohexyl-1-(6-methanesulfonyl-pyridin-3-yl)-cyclopropanecarboxylic acid thiazol-2-ylamide;~~

(±)-(E)-2-Cyclohexyl-1-(4-methanesulfonyl-phenyl)-cyclopropanecarboxylic acid thiazol-2-ylamide;

2-(S)-Cyclohexyl-1-(R)-(4-methanesulfonyl-phenyl)-cyclopropanecarboxylic acid thiazol-2-ylamide;

2-(R)-Cyclohexyl-1-(S)-(4-methanesulfonyl-phenyl)-cyclopropanecarboxylic acid thiazol-2-ylamide;

(±)-(E)-2-Cyclopentylmethyl-1-(4-methanesulfonyl-phenyl)-cyclopropanecarboxylic acid thiazol-2-ylamide;

(±)-(E)-2-Cyclopentyl-1-(4-methanesulfonyl-phenyl)-cyclopropanecarboxylic acid (5-ethyl-[1,3,4]thiadiazol-2-yl)-amide;

~~(±)-(Z)-2-Cyclopentyl-1-(5-[(pyridin-3-ylmethyl)-sulfamoyl]-thiophen-2-yl)-cyclopropanecarboxylic acid thiazol-2-ylamide;~~

~~(±)-(Z)-2-Cyclopentyl-1-(5-methanesulfonyl-thiophen-2-yl)-cyclopropanecarboxylic acid (5-chloro-thiazol-2-yl)-amide;~~

(±)-(E)-2-Cyclohexyl-1-[3-(2-pyridin-2-yl-ethylsulfamoyl)-phenyl]-cyclopropanecarboxylic acid thiazol-2-ylamide;

(±)-(E)-3-Cyclohexyl-2,2-difluoro-1-(4-methanesulfonyl-phenyl)-cyclopropanecarboxylic acid thiazol-2-ylamide;

(±)-(E)-2-Cyclohexyl-1-[4-(2-pyridin-2-yl-ethylsulfamoyl)-phenyl]-cyclopropanecarboxylic acid thiazol-2-ylamide;

(±)-(E)-2-Cyclopentyl-1-(4-methanesulfonyl-phenyl)-cyclopropanecarboxylic acid (5-fluoro-thiazol-2-yl)-amide;

~~(±)-(Z)-2-Cyclohexyl-1-(5-methylsulfamoyl-thiophen-2-yl)-cyclopropanecarboxylic acid thiazol-2-ylamide;~~

~~(±)-(Z)-2-Cyclohexyl-1-(5-methylsulfamoyl-thiophen-2-yl)-cyclopropanecarboxylic acid (5-chloro-thiazol-2-yl)-amide;~~

~~(±)-(Z)-2-Cyclohexyl-1-(5-methanesulfonyl-thiophen-2-yl)-cyclopropanecarboxylic acid (5-chloro-thiazol-2-yl)-amide;~~

(±)-(E)-2-Cyclohexyl-1-(4-methanesulfonyl-3-trifluoromethoxy-phenyl)-cyclopropanecarboxylic acid [1,3,4]thiadiazol-2-ylamide;

(±)-(E)-2-Cyclohexyl-1-(4-methylsulfamoyl-3-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid thiazol-2-ylamide;

(±)-(E)-2-Cyclohexyl-1-(4-methylsulfamoyl-3-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid [1,3,4]thiadiazol-2-ylamide;

(±)-(E)-2-Cyclohexyl-1-(3-nitro-phenyl)-cyclopropanecarboxylic acid thiazol-2-ylamide;

(±)-(E)-4-[2-Cyclopentyl-1-(thiazol-2-ylcarbamoyl)-cyclopropyl]-benzoic acid methyl ester;

(±)-(E)-3-[2-Cyclohexyl-1-(thiazol-2-ylcarbamoyl)-cyclopropyl]-*N*-pyridin-3-ylmethyl-benzamide;

(±)-(E)-3-[2-Cyclohexyl-1-(thiazol-2-ylcarbamoyl)-cyclopropyl]-*N*-methylbenzamide;

(±)-(E)-2-Cyclohexyl-1-(3-methanesulfonylamino-phenyl)-cyclopropanecarboxylic acid thiazol-2-ylamide;

(±)-(E)-2-Cyclohexyl-1-(4-methanesulfonyl-phenyl)-cyclopropanecarboxylic acid (5-methyl-thiazol-2-yl)-amide;

(±)-(E)-2-Cyclohexyl-1-(4-dimethylamino-phenyl)-cyclopropanecarboxylic acid thiazol-2-ylamide;

(E)-2-isopropyl-2-(4-methanesulfonyl-phenyl)-cyclopropane carboxylic acid thiazol-2-ylamide;

(E)-2-cyclohexyl-2-(4-methanesulfonyl-phenyl)-cyclopropane carboxylic acid thiazol-2-ylamide;

(E)-2-cyclopentyl-2-(4-methanesulfonyl-phenyl)-cyclopropane carboxylic acid thiazol-2-ylamide; and

(E)-2-Cyclohexyl-2-(4-methanesulfonyl-phenyl)-cyclopropane carboxylic acid 5-methyl-thiazol-2-ylamide;

or a pharmaceutically acceptable salt thereof.